The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; Celldex; CytomX Therapeutics
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche; Sellas Life Sciences; WindMIL
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche; Sellas Life Sciences; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Novartis; Pieris Pharmaceuticals; Roche
 
Mario Mandalà
Other Relationship - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Michele Del Vecchio
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
 
Helen Gogas
Honoraria - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb; MSD Oncology; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Ana M. Arance
Other Relationship - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Charles Lance Cowey
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Stéphane Dalle
Other Relationship - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Michael Schenker
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gedeon Richter; Gilead Sciences; Helsinn Healthcare; Lilly; Merck Serono; Merck Sharp & Dohme; Mylan; Novartis; Pfizer; PharmaMar; Roche; Synta
 
Vanna Chiarion-Sileni
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ivan Marquez Rodas
Other Relationship - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre; Roche
 
Jean-Jacques Grob
Other Relationship - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche
 
Marcus Butler
Other Relationship - Bristol-Myers Squibb; EMD Serono; Immunocore; Immunovaccine; Merck
 
Mark R. Middleton
Honoraria - Amgen; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; CytomX Therapeutics; Merck; Newlink Genetics; Novartis; RigonTEC
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); RigonTEC (Inst); Roche (Inst); TC Biopharm (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Merck
 
Michele Maio
Other Relationship - AstraZeneca; Incyte; Roche
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Veerle de Pril
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Anila H. Qureshi
No Relationships to Disclose
 
James M. G. Larkin
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Incyte; MedImmune; Merck Serono; Merck Sharp & Dohme; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Syndax
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)